# US 2013/0274831 A1 · Neuromodulatory method for treating chronic or refractory rhinitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274831 A1
- Document ID: US20130274831A1
- Status: Published application
- Kind: A1
- Application number: 13/864,491
- Filed: 2013-04-17
- Published: 2013-10-17
- Earliest claimed: 2012-04-17
- Assignees: The Ohio State University
- Applicants: The Ohio State University
- Inventors: Bradley A. Otto; Ali R. Rezai
- Web page: https://patentgrep.com/patent/US20130274831A1

## CPC

- A61N 1/3606: {adapted for a particular treatment}
- A61N 1/05: for implantation or insertion into the body, e.g. heart electrode (A61N1/06 takes precedence)
- A61N 1/36135: {using physiological parameters}
- A61N 1/36139: {with automatic adjustment}
- A61N 1/3605: {Implantable neurostimulators for stimulating central or peripheral nerve system}
- A61N 1/36053: {adapted for vagal stimulation (A61N1/36114 takes precedence)}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

One aspect of the present disclosure includes a method for treating chronic or refractory rhinitis in a subject. One step of the method includes implanting a therapy delivery system in the subject so that at least one therapy delivery component of the system is positioned substantially adjacent a target location where modulation of the autonomic nervous system (ANS) is effective to treat chronic or refractory rhinitis. The therapy delivery component includes at least one electrode configured to deliver electric current to the target location. Next, electric current is delivered to the at least one electrode to effect a change in the ANS.

## Claims

### Claim 1

A method for treating chronic or refractory rhinitis in a subject, said method comprising the steps of:
implanting a therapy delivery system in the subject so that at least one therapy delivery component of the system is positioned substantially adjacent a target location where modulation of the autonomic nervous system (ANS) is effective to treat chronic or refractory rhinitis, the therapy delivery component including at least one electrode configured to deliver electric current to the target location; and
delivering electric current to the at least one electrode to effect a change in the ANS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target location is a nerve structure associated with the pterygopalatine fossa (PPF).

### Claim 3 (depends on 2)

The method of claim 2, wherein the nerve structure includes at least one of a sphenopalatine ganglion (SPG), a vidian nerve, or a sphenopalatine nerve.

### Claim 4 (depends on 1)

The method of claim 1, wherein modulation of the ANS is effective to alter at least one of mucosal blood flow, mucosal thickness, and mucosal secretion.

### Claim 5 (depends on 1)

The method of claim 1, wherein said step of implanting the therapy delivery system includes positioning the therapy delivery component substantially adjacent a target location where modulation of the parasympathetic nervous system (PNS) and/or the sympathetic nervous system (SNS) is effective to treat chronic or refractory rhinitis.

### Claim 6 (depends on 5)

The method of claim 5, wherein modulation of the PNS comprises substantially blocking or reducing parasympathetic activity.

### Claim 7 (depends on 6)

The method of claim 6, wherein substantially blocking or reducing parasympathetic activity decreases at least one of swelling of nasal mucosa and mucosal secretion.

### Claim 8 (depends on 5)

The method of claim 5, wherein modulation of the SNS comprises substantially activating or increasing sympathetic activity.

### Claim 9 (depends on 8)

The method of claim 8, wherein substantially activating or increasing sympathetic activity decreases at least one of mucosal blood flow, and mucosal thickness.

### Claim 10 (depends on 2)

The method of claim 2, wherein delivery of electric current to the at least one electrode modulates afferent neuronal activity.

### Claim 11 (depends on 2)

The method of claim 2, wherein delivery of electric current to the at least one electrode modulates efferent neuronal activity.

### Claim 12

A method for treating chronic or refractory rhinitis in a subject, said method comprising the steps of:
implanting a closed-loop therapy delivery system in the subject so that at least one therapy delivery component of the system is positioned substantially adjacent a target location where modulation of the ANS is effective to treat chronic or refractory rhinitis, the therapy delivery component including at least one electrode configured to deliver electric current to the target location;
delivering electric current to the at least one electrode to effect a change in the ANS;
sensing, by the therapy delivery system, of at least one physiological parameter associated with chronic or refractory rhinitis; and
activating the therapy delivery component of the system to adjust application of electric current to the target site in response to the sensed at least one physiological parameter.

### Claim 13 (depends on 12)

The method of claim 12, wherein the target location is a nerve structure associated with the PPF.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nerve structure includes at least one of a SPG, a vidian nerve, or a sphenopalatine nerve.

### Claim 15 (depends on 12)

The method of claim 12, wherein modulation of the ANS is effective to alter at least one of mucosal blood flow, mucosal thickness, and mucosal secretion.

### Claim 16 (depends on 12)

The method of claim 12, wherein said step of implanting the closed-loop therapy delivery system includes positioning the therapy delivery component substantially adjacent a target location where modulation of the PNS and/or SNS is effective to treat chronic or refractory rhinitis.

### Claim 17 (depends on 12)

The method of claim 12, wherein said sensing step further comprises:
generating a sensor signal based on the sensed at least one physiological parameter; and
activating the therapy delivery system to adjust application of electric current to the target site in response to the sensor signal to treat chronic or refractory rhinitis.

### Claim 18

A method for moistening a nasal passage of a subject, said method comprising the steps of:
implanting a therapy delivery system in the subject so that at least one therapy delivery component of the system is positioned substantially adjacent a target location where modulation of the autonomic nervous system (ANS) is effective to moisten the nasal passage, the therapy delivery component including at least one electrode configured to deliver electric current to the target location; and
delivering electric current to the at least one electrode to effect a change in the ANS.

### Claim 19 (depends on 18)

The method of claim 18, wherein the target location is a nerve structure associated with the PPF.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nerve structure includes at least one of a SPG, a vidian nerve, or a sphenopalatine nerve.
